Age at vaccination and timing of infection do not alter vaccine-associated enhanced respiratory disease in influenza A virus infected pigs.

Age at vaccination and timing of infection do not alter vaccine-associated enhanced respiratory disease in influenza A virus infected pigs. Clin Vaccine Immunol. 2016 Mar 30; Authors: Souza CK, Rajão DS, Loving CL, Gauger PC, Pérez DR, Vincent AL Abstract Whole inactivated virus (WIV) vaccines are widely used in the swine industry to reduce clinical disease against homologous influenza A virus (IAV) infection. In pigs experimentally challenged with antigenically distinct heterologous IAV of the same hemagglutinin subtype, WIV vaccinates have been shown to develop vaccine-associated enhanced respiratory disease (VAERD). We evaluated the impact of vaccine valency, age at vaccination, and duration between vaccination and challenge on development of VAERD using vaccine containing δ1-H1N2 and challenge with pandemic H1N1 (pH1N1) virus. Pigs were vaccinated with monovalent WIV MN08 (δ1-H1N2) and bivalent (δ1-H1N2/H3N2) or (δ1-H1N2/pH1N1) vaccines then were challenged with pH1N1 at 3 weeks post-boost (wpb). Another group was vaccinated with the same monovalent WIV followed by challenge at 6 wpb to determine if time post-vaccination plays a role in development of VAERD. In a follow up study, the impact of age of first WIV vaccination (4 versus 9 weeks of age) with a boost three weeks later (7 versus 12 weeks of age) was evaluated. A monovalent live-attenuated influenza virus (LAIV) vaccine administered at 4 and 7 weeks of age was also ...
Source: Clinical and Vaccine Immunology - Category: Allergy & Immunology Authors: Tags: Clin Vaccine Immunol Source Type: research